Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Danaher Q3 2026 Results: Net Income $1.24B, Up 36.0% YoY

Danaher Corporation reported a significant increase in net earnings from continuing operations to $3.1 billion for the nine months ended September 25, 2026, compared to $2.4 billion in the prior year. The company executed substantial acquisition activity, spending $9.9 billion on cash acquisitions, which contributed to a notable increase in goodwill and intangible assets on the balance sheet.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue6,554.06,053.0
Gross profit3,837.03,523.0
Profit before tax1,132.01,076.0
Net income1,235.0908.0
EPS (diluted, $ a share)$1.75$1.27

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+36.0%
Revenue, year on year+8.3%
Gross margin58.5%
Operating margin19.0%
Source

10-Q filed with the SEC, NYSE: DHR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Danaher Corp: key numbers

Share price
$229.91Close, Nov 16
Market cap
$162B
Shares outstanding
703.53MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Industrial Instruments For Measurement, Display, and ControlSIC 3823

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Danaher Corp

All →
5:00 PM ET Form 4
Insider Selling

Danaher EVP Gregory M. Milosevich Sells $484K of Stock

Gregory M. Milosevich, EVP, sold 2,100 shares of Danaher Corp at $230.62 a share, worth $484K in total on Nov 9, 2026. Shares held after the trade: 22,367 (-8.6%).

Value
$484K
Shares
2,100
Price
$230.62
Role
EVP
Holding change
-8.6%
Trade date
Nov 9, 2026
5:00 PM ET Form 4
Insider Selling

Danaher EVP Matthew McGrew Sells $4.1M of Stock

Matthew McGrew, EVP, sold 17,385 shares of Danaher Corp at $235.69 a share, worth $4.1M in total on Nov 9, 2026. Shares held after the trade: 12,674 (-57.8%).

Value
$4.1M
Shares
17,385
Price
$235.69
Role
EVP
Holding change
-57.8%
Trade date
Nov 9, 2026
5:01 PM ET Form 4
Insider Selling

Danaher VP, CAO Christopher Bouda Sells $1.78M of Stock

Christopher Bouda, VP, CAO, sold 7,598 shares of Danaher Corp at $234.54 to $234.58 a share (average $234.56) in 2 transactions, worth $1.78M in total on Oct 28, 2026. Shares held after the trade: 9,107 (-26.3%).

Value
$1.78M
Shares
7,598
Average price
$234.56
Role
VP, CAO
Holding change
-26.3%
Trade date
Oct 28, 2026
5:00 PM ET Form 4
Insider Selling

Danaher EVP Matthew McGrew Sells $7.01M of Stock

Matthew McGrew, EVP, sold 29,754 shares of Danaher Corp at $235.35 to $236.09 a share (average $235.74) in 2 transactions, worth $7.01M in total on Oct 28, 2026. Shares held after the trade: 12,674 (-55.2%).

Value
$7.01M
Shares
29,754
Average price
$235.74
Role
EVP
Holding change
-55.2%
Trade date
Oct 28, 2026
6:01 AM ET 8-K
Financial Results

Danaher Financial Results

Danaher reported third quarter 2026 revenues of $6.6 billion, an 8.5% increase year-over-year, with net earnings rising 34.5% to $1.2 billion. The company raised its full-year 2026 adjusted diluted net earnings per share guidance to a range of $8.57 to $8.62, citing improving trends across end markets.

Term
Q3 2026

“We delivered better-than-expected third quarter revenue, earnings and cash flow, and are encouraged by the improving trends we saw across our end markets. The continued acceleration in core revenue growth excluding respiratory revenue, together with DBS-driven execution drove double-digit adjusted EPS growth and underscored our ability to convert improving demand into strong financial performance.”

Julie Sawyer Montgomery, President and Chief Executive Officer

“Looking forward, the opportunity for Danaher is clear: to become the defining leader in Life Sciences and Diagnostics–a company that unambiguously gains share, delivers sustainable profitable growth, and helps our customers improve outcomes for patients around the world.”

Julie Sawyer Montgomery, President and Chief Executive Officer
8:53 AM ET 8-K
Leadership Change

Danaher Leadership Change

Danaher Corporation increased its Board of Directors to thirteen members and appointed Daniel L. Comas and Robert M. Hershberg as new directors, effective October 9, 2026. Mr. Comas is the company's former CFO, and Dr. Hershberg is the former CEO of HilleVax, Inc. Both will serve until the next annual meeting and participate in the standard non-employee director compensation program.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.